Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2749381 | 0.87 | CA1 (0.40) | TRPV4HSD11B1CCR2AKR1C3AKR1C2 | |
| SCHEMBL30014353 | 0.87 | TRPV4 (0.44) | TRPV4MCL1APPDDR1AHR | |
| SCHEMBL15881879 | 0.87 | TRPV4 (0.44) | TRPV4MCL1APPDDR1AHR | |
| SCHEMBL29764204 | 0.75 | TRPV4 (0.39) | TRPV4MCL1CCR2 | |
| SCHEMBL17468 | 0.75 | TRPV4 (0.39) | TRPV4MCL1CCR2 | |
| SCHEMBL29764203 | 0.75 | TRPV4 (0.39) | TRPV4MCL1CCR2 | |
| SCHEMBL29899701 | 0.74 | AKR1B1 (0.46) | TRPV4CCR2AHR | |
| SCHEMBL113810 | 0.74 | AKR1B1 (0.46) | TRPV4CCR2AHR | |
| SCHEMBL31292340 | 0.73 | CNR2 (0.44) | AKR1C3AKR1C2 | |
| SCHEMBL1029355 | 0.72 | TRPV4 (0.53) | TRPV4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |